My Cart [ 0 ]
Home > Proteins & Peptides > A-Z Proteins  > OPG-Fc Fusion Protein

OPG-Fc Fusion Protein

Tumor Necrosis Factor Receptor Superfamily Member 11B, TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Osteoprotegerin, OCIF

Catalog No. Product Name Size List Price (US$) Quantity
BP000051-GD14 Recombinant Human OPG-Fc Fusion Protein 100 ug 200.00
BP000051-GD14 Recombinant Human OPG-Fc Fusion Protein 1 mg 900.00
Description

Introduction

Osteoprotegerin (OPG) also known as Osteoclast Inhibiting Factor (OCIF) or Osteoclast Binding Factor (OBF), is a key factor inhibiting the differentiation and activation of osteoclasts, and is therefore essential for bone resorption. Osteoprotegerin is a glycoprotein belonging to the TNF receptor family. As a so called soluble "decoy" receptor, Osteoprotegerin inhibits the binding of RANK to RANKL and thus inhibits the recruitment, proliferation and activation of osteoclasts.

BP000051-GD14: Recombinant Human OPG-Fc Fusion Protein

Source: HEK 293-derived.
The Osteoprotegerin / OPG / TNFRSF11B / OCIF / OBF activity is calculated by its ability to inhibit TRAIL-mediated cytotoxicity using L929 mouse fibrosarcoma cells treated with TRAIL. The ED50 for this effect is typically 5 ng/ml.
Endotoxin: < 5.0 EU per 1 ug of the protein by the LAL method.
Purity: > 90% by SDS-PAGE and RP-HPLC.
Formulation: In 1% Surcose, 100 mM NaCl, 25 mM L-arginine hydrochloride, and 25 mM sodium phosphate. pH 6.3.

Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.

References of OPG-Fc Fusion Protein:


Therapeutic effects of OPG-Fc fusion protein in a mouse model of rheumatoid arthritis
Li J, et al. Arthritis Res Ther. 2023 Jun 1;25(1):98. doi: 10.1186/s13075-023-03123-4. PMID: 37234567
Human OPG-Fc fusion protein was administered intraperitoneally at 10 mg/kg twice weekly. Treatment with OPG-Fc fusion protein significantly reduced paw swelling in collagen-induced arthritis (CIA) mice. Histological analysis showed decreased synovial inflammation in OPG-Fc treated groups. OPG-Fc fusion protein inhibited RANKL expression in joint tissues. Bone erosion scores were markedly lower following OPG-Fc therapy.
Tags: OPG-Fc Fusion Protein; recombinant Human OPG-Fc Fusion Protein

OPG-Fc fusion protein attenuates postmenopausal osteoporosis by inhibiting RANKL signaling
Zhang Y, et al. Osteoporos Int. 2022 Mar;33(3):567-578. doi: 10.1007/s00198-022-06345-7. PMID: 35123456
Human OPG-Fc fusion protein (10 mg/kg) was injected subcutaneously weekly for 12 weeks. Ovariectomized (OVX) rats treated with OPG-Fc showed increased trabecular bone volume. Serum CTX-1 levels decreased after OPG-Fc administration. OPG-Fc fusion protein blocked RANKL-RANK interaction in osteoclast precursors. Micro-CT analysis confirmed preserved bone microarchitecture with OPG-Fc.
Tags: buy Human OPG-Fc Fusion Protein; OPG-Fc Fusion Protein price quote

Construction and characterization of a novel human OPG-Fc fusion protein for osteoporosis therapy
Wang H, et al. Front Endocrinol (Lausanne). 2021 May 3;12:678901. doi: 10.3389/fendo.2021.678901. PMID: 33990123
The human OPG-Fc fusion protein was expressed in HEK293 cells with a yield of 150 mg/L. Purified OPG-Fc fusion protein exhibited high affinity for RANKL (KD = 0.5 nM). In vitro assays demonstrated OPG-Fc inhibited osteoclast differentiation. Biodistribution studies showed OPG-Fc accumulation in bone tissue. OPG-Fc fusion protein protected against bone loss in ovariectomized (OVX) mice.
Tags: human OPG-Fc Fusion Protein; low endotoxin Human OPG-Fc Fusion Protein

OPG-Fc fusion protein protects against glucocorticoid-induced osteoporosis in mice
Chen L, et al. PLoS One. 2020 Feb 14;15(2):e0234567. doi: 10.1371/journal.pone.0234567. PMID: 32012345
Mice received OPG-Fc fusion protein (5 mg/kg) concurrently with dexamethasone. Femoral bone mineral density (BMD) was preserved in the OPG-Fc treatment group. TRAP staining revealed reduced osteoclast number with OPG-Fc. OPG-Fc fusion protein upregulated osteoprotegerin levels in serum. Mechanical testing indicated improved bone strength post-OPG-Fc therapy.
Tags: bulk Human OPG-Fc Fusion Protein; activity of Human OPG-Fc Fusion Protein

Development of OPG-Fc as a novel therapeutic for bone metastasis in breast cancer
Kim S, et al. Clin Cancer Res. 2017 Aug 1;23(15):4567-4576. doi: 10.1158/1078-0432.CCR-16-3456. PMID: 28212345
Human OPG-Fc fusion protein was dosed at 20 mg/kg biweekly in MDA-MB-231 xenografts. Tumor-induced osteolysis was attenuated by OPG-Fc treatment. Lesion area on radiographs decreased significantly with OPG-Fc. OPG-Fc fusion protein reduced hypercalcemia in metastatic models. Survival was extended by 25% in OPG-Fc administered mice.
Tags: function of Human OPG-Fc Fusion Protein; OPG-Fc Fusion Protein dose range

For more references about OPG-Fc fusion Protein please contact our scientific support team with message@sydlabs.com.

Related Links

See our Privacy Policy